Giovanni Paganelli
#157,276
Most Influential Person Now
Researcher
Giovanni Paganelli's AcademicInfluence.com Rankings
Giovanni Paganellicomputer-science Degrees
Computer Science
#8726
World Rank
#9175
Historical Rank
Computational Linguistics
#1995
World Rank
#2016
Historical Rank
Machine Learning
#3648
World Rank
#3693
Historical Rank
Artificial Intelligence
#3960
World Rank
#4017
Historical Rank
Download Badge
Computer Science
Giovanni Paganelli's Degrees
- PhD Computer Science University of California, Berkeley
- Masters Computer Science University of California, Berkeley
- Bachelors Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is Giovanni Paganelli Influential?
(Suggest an Edit or Addition)Giovanni Paganelli's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. (2003) (2009)
- Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes (1997) (1934)
- Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. (1999) (785)
- Sentinel Lymph Node Biopsy in Breast Cancer: Ten-Year Results of a Randomized Controlled Study (2010) (495)
- Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. (2006) (428)
- Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. (2005) (376)
- Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. (2006) (335)
- Radioguided sentinel lymph node biopsy in breast cancer surgery. (2001) (335)
- Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study (2011) (332)
- Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors (2014) (316)
- Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study (2003) (309)
- Intraoperative examination of axillary sentinel lymph nodes in breast carcinoma patients (1999) (281)
- Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. (1991) (269)
- Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors (2008) (262)
- 68Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine Tumors (2010) (232)
- Safety of sentinel node biopsy in pregnant patients with breast cancer. (2004) (227)
- Lymphoscintigraphy and radioguided biopsy of the sentinel axillary node in breast cancer. (1998) (225)
- Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours (2004) (217)
- Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide (2001) (217)
- 111In- and 90Y-DOTA-Lanreotide: Results and implications of the MAURITIUS trial (2002) (213)
- Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in a single institution (2005) (211)
- Predicting the Risk for Additional Axillary Metastases in Patients With Breast Carcinoma and Positive Sentinel Lymph Node Biopsy (2005) (207)
- Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin (1999) (203)
- Dosimetry in Peptide radionuclide receptor therapy: a review. (2006) (201)
- Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. (2007) (194)
- Sentinel node biopsy in breast cancer: early results in 953 patients with negative sentinel node biopsy and no axillary dissection. (2005) (187)
- Lung cancer screening with low-dose computed tomography: a non-invasive diagnostic protocol for baseline lung nodules. (2008) (171)
- Axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. (2003) (167)
- Comparison of radioguided excision with wire localization of occult breast lesions (1999) (167)
- Sentinel node biopsy in early vulvar cancer (2000) (159)
- Sentinel lymph node biopsy as an indicator for axillary dissection in early breast cancer. (2001) (158)
- Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. (2009) (153)
- Biokinetics and dosimetry in patients administered with 111In-DOTA-Tyr3-octreotide: implications for internal radiotherapy with 90Y-DOTATOC (1999) (150)
- Pretargeted adjuvant radioimmunotherapy with Yttrium-90-biotin in malignant glioma patients: A pilot study (2002) (147)
- Radioguided surgery of occult breast lesions. (1998) (138)
- Sentinel Node Biopsy Is Not a Standard Procedure in Ductal Carcinoma In Situ of the Breast: The Experience of the European Institute of Oncology on 854 Patients in 10 Years (2008) (134)
- A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. (2007) (132)
- Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results. (2001) (132)
- The use of standardized uptake values for assessing FDG uptake with PET in oncology: a clinical perspective (2004) (129)
- Radioguided sentinel lymph node biopsy in malignant cutaneous melanoma. (2002) (127)
- Optimized sentinel node scintigraphy in breast cancer. (1998) (124)
- Radioguided occult lesion localisation (ROLL) and surgical biopsy in breast cancer. Technical aspects. (2002) (124)
- Sentinel lymph node biopsy in pregnant patients with breast cancer (2009) (122)
- The value of radiotherapy on metastatic internal mammary nodes in breast cancer. Results on a large series. (2008) (120)
- Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group. (2002) (118)
- Sentinel node in breast cancer procedural guidelines (2007) (116)
- Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours (2013) (115)
- 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies. (2002) (114)
- Dosimetry for treatment with radiolabelled somatostatin analogues. A review. (2010) (113)
- Intraperitoneal radio‐localization of tumors pre‐targeted by biotinylated monoclonal antibodies (1990) (113)
- Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma (2009) (112)
- PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis (2018) (110)
- Monoclonal antibody pretargetting techniques for tumour localization: the avidin‐biotin system (1991) (110)
- In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. (2002) (110)
- Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity. (1998) (109)
- Use of technetium-99m-labeled colloid albumin for preoperative and intraoperative localization of nonpalpable breast lesions. (2000) (109)
- Comparative Evaluation of an Extensive Histopathologic Examination and a Real-Time Reverse-Transcription-Polymerase Chain Reaction Assay for Mammaglobin and Cytokeratin 19 on Axillary Sentinel Lymph Nodes of Breast Carcinoma Patients (2008) (108)
- Peptide receptor therapies in neuroendocrine tumors (2009) (107)
- Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (2016) (102)
- Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone (2014) (99)
- Axillary metastases in breast cancer patients with negative sentinel nodes: a follow-up of 3548 cases. (2009) (98)
- Is there a role for sentinel node biopsy in early N0 tongue tumors? (2000) (94)
- Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas. (2004) (94)
- Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors (2008) (93)
- 177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study (2014) (93)
- Sentinel node biopsy in head and neck cancer. (2001) (93)
- Long-term results of PRRT in advanced bronchopulmonary carcinoid (2016) (92)
- Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients (1999) (91)
- Internal mammary node lymphoscintigraphy and biopsy in breast cancer. (2002) (90)
- Treatment with the Radiolabelled Somatostatin Analog 177Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors (2013) (90)
- The sentinel node biopsy after previous breast surgery: preliminary results on 543 patients treated at the European Institute of Oncology (2004) (89)
- Sentinel Lymph Node Metastasis in Microinvasive Breast Cancer (2004) (86)
- PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy (2018) (86)
- Role of positron emission tomography scanning in the management of lung nodules detected at baseline computed tomography screening. (2007) (85)
- Radioguided occult lesion localization (ROLL) in breast cancer: maximizing efficacy, minimizing mutilation. (2002) (82)
- Sentinel lymph node biopsy for localised ductal carcinoma in situ? (2005) (82)
- Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE (2017) (80)
- A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management (2016) (80)
- 18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide (2015) (79)
- Tumor cell targeting with antibody-avidin complexes and biotinylated tumor necrosis factor alpha. (1997) (78)
- Radiation protection in radioguided surgery of breast cancer. (1999) (78)
- In vivo labelling of biotinylated monoclonal antibodies by radioactive avidin: A strategy to increase tumor radiolocalization (1988) (77)
- Occult Breast Lesion Localization plus Sentinel Node Biopsy (SNOLL): Experience with 959 Patients at the European Institute of Oncology (2007) (76)
- Kidney Dosimetry in 177Lu and 90Y Peptide Receptor Radionuclide Therapy: Influence of Image Timing, Time-Activity Integration Method, and Risk Factors (2013) (75)
- Presurgical identification of hibernating myocardium by combined use of technetium-99m hexakis 2-methoxyisobutylisonitrile single photon emission tomography and fluorine-18 fluoro-2-deoxy-d-glucose positron emission tomography in patients with coronary artery disease (2004) (75)
- Optimised nuclear medicine method for tumour marking and sentinel node detection in occult primary breast lesions (2004) (72)
- Calculation of electron and isotopes dose point kernels with FLUKA Monte Carlo code for dosimetry in nuclear medicine therapy. (2011) (72)
- Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Individuals with Neck or Mediastinal Paraganglioma (PGL) (2012) (71)
- Second Biopsy of Axillary Sentinel Lymph Node for Reappearing Breast Cancer After Previous Sentinel Lymph Node Biopsy (2005) (70)
- Lymphoscintigraphic and intraoperative detection of the sentinel lymph node in breast cancer patients: The nuclear medicine perspective (2004) (67)
- Sentinel node biopsy in male breast cancer (2004) (67)
- 68Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients (2018) (65)
- Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide. (2004) (65)
- Development of axillary surgery in breast cancer. (2005) (64)
- Detection of prosthetic vascular graft infection using avidin/indium-111-biotin scintigraphy. (1996) (64)
- Radioembolisation with 90Y-microspheres: dosimetric and radiobiological investigation for multi-cycle treatment (2008) (63)
- IgEs targeted on tumor cells: therapeutic activity and potential in the design of tumor vaccines. (2001) (62)
- Computed tomography-guided preoperative radiotracer localization of nonpalpable lung nodules. (2010) (61)
- Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3-Octreotide: preliminary report in cancer patients. (1999) (61)
- Peptide receptor radionuclide therapy with 177Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and 18F-FDG PET (2016) (60)
- Human biodistribution, dosimetry and clinical use of technetium(III)-99m-Q12. (1994) (60)
- Radioimmunotherapy with Radretumab in Patients with Relapsed Hematologic Malignancies (2012) (59)
- Erratum to: 18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide (2015) (58)
- Sentinel node localization in primary melanoma: preoperative dynamic lymphoscintigraphy, intraoperative gamma probe, and vital dye guidance. (2000) (57)
- Quantitative analysis of 90Y Bremsstrahlung SPECT-CT images for application to 3D patient-specific dosimetry. (2009) (57)
- Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study (2020) (57)
- Characterization of poultry egg-white avidins and their potential as a tool in pretargeting cancer treatment. (2003) (55)
- High-Dose Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan: Comparative Dosimetric Study for Tailored Treatment (2007) (54)
- Yttrium-labelled peptides for therapy of NET (2012) (54)
- Lymphatic mapping to tailor selective lymphadenectomy in cN0 tongue carcinoma: beyond the sentinel node concept (2006) (53)
- Recent issues on dosimetry and radiobiology for peptide receptor radionuclide therapy. (2011) (52)
- PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest (2019) (52)
- Two-step tumour targetting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin (2004) (51)
- Investigation of receptor radionuclide therapy with 177Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index (2018) (51)
- Antibody‐guided diagnosis: An italian experience on cea‐expressing tumours (1988) (50)
- Peptide receptor radionuclide therapy for advanced neuroendocrine tumors. (2014) (50)
- Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues. (2010) (49)
- A novel radioguided surgery technique exploiting β− decays (2014) (49)
- The three-step pretargeting approach reduces the human anti-mouse antibody response in patients submitted to radioimmunoscintigraphy and radioimmunotherapy (1997) (49)
- Poly(ethylene glycol)-avidin bioconjugates: suitable candidates for tumor pretargeting. (2002) (48)
- Sentinel lymph node biopsy in multicentric breast cancer. The experience of the European Institute of Oncology. (2006) (48)
- Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT®) (2006) (47)
- Tumor pretargeting: role of avidin/streptavidin on monoclonal antibody internalization. (1997) (47)
- Clinical validation of the avidin/indium-111 biotin approach for imaging infection/inflammation in orthopaedic patients (1999) (47)
- Feasibility and utility of re-treatment with 177Lu-DOTATATE in GEP-NENs relapsed after treatment with 90Y-DOTATOC (2015) (47)
- Sentinel node localization in cutaneous melanoma: lymphoscintigraphy with colloids and antibody fragments versus blue dye mapping (1998) (46)
- A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary (2006) (46)
- CAR-T cell therapy: a potential new strategy against prostate cancer (2019) (46)
- Role of [18F]FDG-PET/CT after radiofrequency ablation of liver metastases: preliminary results (2008) (45)
- High activity 90Y‐ibritumomab tiuxetan (Zevalin®) with peripheral blood progenitor cells support in patients with refractory/resistant B‐cell non‐Hodgkin lymphomas (2007) (45)
- Quantitative comparison of direct antibody labeling and tumor pretargeting in uveal melanoma. (1996) (44)
- Radioimmunotherapy of brain tumor (2006) (44)
- Detection of Sentinel Nodes by Lymphoscintigraphy and Gamma Probe Guided Surgery in Vulvar Neoplasia (2000) (44)
- Gene transcript analysis blood values correlate with 68Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status (2015) (43)
- Yttrium-90 Ibritumomab Tiuxetan (Zevalin) for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Appropriate for Autologous Stem Cell Transplantation: Results of an Open-Label Phase II Trial. (2004) (43)
- Therapeutic use of avidin is not hampered by antiavidin antibodies in humans. (2010) (43)
- Radiation protection in radionuclide therapies with 90Y-conjugates: risks and safety (2006) (42)
- Radioimmunotherapy in advanced ovarian cancer: is there a role for pre-targeting with (90)Y-biotin? (2004) (41)
- Positron emission tomography in the diagnostic work-up of screening-detected lung nodules (2014) (41)
- The evolution of the conservative approach to breast cancer. (2007) (41)
- Pretargeting strategies for radio-immunoguided tumour localisation and therapy. (1997) (41)
- Treatment of a pituitary metastasis from a neuroendocrine tumour: case report and literature review (2007) (40)
- Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma (2005) (40)
- Combined treatment of advanced oropharyngeal cancer with external radiotherapy and three-step radioimmunotherapy (1998) (40)
- Imaging of lung hamartomas by multidetector computed tomography and positron emission tomography. (2008) (40)
- Biochemical characterization and crystal structure of a recombinant hen avidin and its acidic mutant expressed in Escherichia coli. (1998) (40)
- Novel antitenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRITR) (2003) (39)
- Receptor radionuclide therapy of tumors: a road from basic research to clinical applications. (2006) (39)
- Use of the FLUKA Monte Carlo code for 3D patient-specific dosimetry on PET-CT and SPECT-CT images (2013) (39)
- Sentinel lymph node biopsy is feasible even after total mastectomy (2007) (39)
- Role of multidetector CT and FDG-PET/CT in the diagnosis of local and distant recurrence of resected rectal cancer (2007) (38)
- Conservative Treatment of Breast Cancer: Its Evolution (2005) (38)
- Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas. (2010) (38)
- Intraoperative avidination for radionuclide treatment as a radiotherapy boost in breast cancer: results of a phase II study with 90Y-labeled biotin (2010) (38)
- Intraoperative localization of the sentinel node in breast cancer: technical aspects of lymphoscintigraphic methods. (1998) (37)
- A new biotin derivative-DOTA conjugate as a candidate for pretargeted diagnosis and therapy of tumors. (2003) (37)
- Lymphocytic toxicity in patients after peptide-receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC. (2009) (37)
- Imaging osteomyelitis with streptavidin and indium-111-labeled biotin. (1996) (36)
- Pretargeting of Carcinomas with the Avidin-Biotin System (1993) (36)
- Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life (2017) (35)
- Sentinel node detection in pre-operative axillary staging (2004) (35)
- Innovation in early breast cancer surgery: radio-guided occult lesion localization and sentinel node biopsy. (2002) (34)
- Improved Tumor Targeting by Combined Use of Two Antitenascin Antibodies (2005) (32)
- Radioimmunoguided surgery using iodine-125-labeled biotinylated monoclonal antibodies and cold avidin. (1994) (32)
- Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid) (2006) (31)
- Analysis of overall survival by number of radium-223 injections received in an international expanded access program (iEAP). (2016) (30)
- Oligometastatic non-small cell lung cancer: a multidisciplinary approach in the positron emission tomographic scan era. (2007) (30)
- Is [18F] fluorodeoxyglucose uptake by the primary tumor a prognostic factor in breast cancer? (2013) (30)
- Membrane IgE Binds and Activates FcεRI in an Antigen-Independent Manner1 (2005) (30)
- Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice (2019) (29)
- Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients (2020) (28)
- MRI, antibody-guided scintigraphy, and glucose metabolism in uveal melanoma. (1992) (28)
- IART: intraoperative avidination for radionuclide treatment. A new way of partial breast irradiation. (2007) (28)
- Dosimetric model for locoregional treatments of brain tumors with 90Y-conjugates: clinical application with 90Y-DOTATOC. (2006) (28)
- Optimization of Axillary Lymphoscintigraphy to Detect the Sentinel Node in Breast Cancer (1997) (27)
- Dosimetry of 177Lu-PSMA-617 after Mannitol Infusion and Glutamate Tablet Administration: Preliminary Results of EUDRACT/RSO 2016-002732-32 IRST Protocol (2019) (26)
- Sentinel node detection by lymphoscintigraphy and sentinel lymph node biopsy in vulvar melanoma (2010) (26)
- Reduction of 68Ga-PSMA renal uptake with mannitol infusion: preliminary results (2017) (26)
- Immunoscintigraphy with three step monoclonal pretargeting technique in diagnosis of uveal melanoma: preliminary results. (1994) (26)
- Biodistribution in tumour‐bearing mice of two 90Y‐labelled biotins using three‐step tumour targeting (1997) (25)
- Adoptive immunotherapy by avidin-driven cytotoxic T lymphocyte-tumor bridging. (2000) (24)
- Prognostic value of 18F–choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide (2018) (24)
- Results and Implications of the MAURITIUS Trial (2002) (24)
- Joint uptake and body distribution of a technetium-99m-labeled anti-rat-CD4 monoclonal antibody in rat adjuvant arthritis. (1993) (24)
- Role of sentinel lymph node biopsy in oral cancer. (2006) (24)
- Peptide receptor radionuclide therapy in a case of multiple spinal canal and cranial paragangliomas. (2011) (23)
- Diagnosis of persistent ovarian carcinoma with three-step immunoscintigraphy (2000) (23)
- Circulating levels of VCAM and MMP-2 may help identify patients with more aggressive prostate cancer. (2008) (23)
- Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis (2020) (23)
- Nonpalpable breast carcinomas: long-term evaluation of 1,258 cases. (2010) (23)
- Sentinel node biopsy: role of nuclear medicine in conservative surgery of breast cancer (1998) (23)
- Risk Factors for Overall Survival Outcome in Surgically Treated Human Papillomavirus-Negative and Positive Patients with Oropharyngeal Cancer. (2017) (23)
- Improved radiotracing of oxytocin receptor-expressing tumours using the new [111In]-DOTA-Lys8-deamino-vasotocin analogue (2003) (23)
- The sentinel lymph node biopsy under local anesthesia in breast carcinoma: experience of the European Institute of Oncology and impact on quality of life (2004) (22)
- Low and High Tenascin-Expressing Tumors Are Efficiently Targeted by ST2146 Monoclonal Antibody (2006) (22)
- Outcome of treating advanced neuroendocrine tumours with radiolabelled somatostatin analogues (2009) (22)
- Sentinel node localization by lymphoscintigraphy: a reliable technique with widespread applications. (2000) (22)
- Intraoperative Avidination for Radionuclide Therapy: A Prospective New Development to Accelerate Radiotherapy in Breast Cancer (2007) (22)
- AvidinOX for highly efficient tissue-pretargeted radionuclide therapy. (2010) (22)
- Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors (2021) (21)
- Sentinel node localization in primary melanoma: learning curve and results. (1999) (21)
- Dosimetry in radionuclide therapies with 90Y-conjugates: the IEO experience. (2000) (21)
- Three-step tumor pre-targeting in lung cancer immunoscintigraphy. (1993) (21)
- Radioguided localisation (ROLL) of non-palpable breast lesions and simultaneous sentinel lymph node biopsy (SNOLL): the experience of the European Institute of Oncology (2007) (21)
- A novel radioguided surgery technique exploiting b 2 decays (2014) (20)
- PET/CT in Multiple Myeloma: Beyond FDG (2021) (20)
- An unusual breast lesion: the ultrasonographic, mammographic, MRI and nuclear medicine findings of mammary hibernoma. (2010) (20)
- Quantitative accuracy of 177Lu SPECT imaging for molecular radiotherapy (2017) (20)
- Avidin and 111In-labelled biotin scan: a new radioisotopic method for localising vascular graft infection. (1995) (19)
- The Hypofunctional Effect of P335L Single Nucleotide Polymorphism on SSTR5 Function (2011) (18)
- Avidin-biotin system in Radioimmunoguided surgery for colorectal cancer (1994) (17)
- Efficacy of 90Yttrium‐ibritumomab tiuxetan in relapsed/refractory extranodal marginal‐zone lymphoma (2014) (17)
- Clinical evidence of abscopal effect in cutaneous squamous cell carcinoma treated with diffusing alpha emitters radiation therapy: a case report (2019) (17)
- OXavidin for Tissue Targeting Biotinylated Therapeutics (2010) (17)
- Pre-targeted immunodetection in glioma patients: tumour localization and single-photon emission tomography imaging of [99mTc]PnAO-biotin (1994) (17)
- Preparation and characterization of active site protected poly(ethylene glycol)-avidin bioconjugates. (2005) (17)
- Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer (2020) (17)
- Localization of avidin in superficial bladder cancer: a potentially new approach for radionuclide therapy. (2003) (17)
- Ipilimumab-induced immunomediated adverse events: possible pitfalls in (18)F-FDG PET/CT interpretation. (2014) (17)
- Pre-targeted immunodetection in glioma patients: tumour localization and single-photon emission tomography imaging of [99mTc]PnAO-biotin (2004) (16)
- Vascular tumor targeting. (2006) (16)
- Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods? (2003) (16)
- Evaluation of response to immunotherapy: new challenges and opportunities for PET imaging (2014) (16)
- The sentinel node biopsy under local anesthesia in breast cancer: advantages and problems, how the technique influenced the activity of a breast surgery department; update from the European Institute of Oncology with more than 1000 cases. (2007) (16)
- Therapeutic schemes in 177Lu and 90Y-PRRT: radiobiological considerations. (2017) (15)
- Targeted bone marrow radioablation with 153Samarium-lexidronam promotes allogeneic hematopoietic chimerism and donor-specific immunologic hyporesponsiveness (2004) (15)
- Localization of biotinylated monoclonal antibody in nude mice bearing subcutaneous and intraperitoneal human tumour xenografts (1988) (15)
- Pretargeted immunoscintigraphy in patients with medullary thyroid carcinoma. (1996) (15)
- Positron emission tomography for the detection of colorectal adenomas. (2010) (15)
- Atypical primary pulmonary meningioma: a report of a case suspected of being a lung metastasis (2014) (15)
- Clinical Application of Spectral Electromagnetic Interaction in Breast Cancer: Diagnostic Results of a Pilot Study (2006) (15)
- Three-step immunoscintigraphy with anti-chromogranin A monoclonal antibody in tumours of the pituitary region. (1996) (15)
- 3D dosimetry in patients with early breast cancer undergoing Intraoperative Avidination for Radionuclide Therapy (IART®) combined with external beam radiation therapy (2012) (15)
- The role of dosimetry in the high activity 90Y-ibritumomab tiuxetan regimens: two cases of abnormal biodistribution. (2009) (14)
- High Dose Zevalin (90Yttrium Ibritumomab Tiuxetan) Treatment with PBSC Support in Refractory-Resistant NHL Patients: Preliminary Results of a Phase I/II Study. (2005) (14)
- A new method for faster blood clearance in radioimmuno-guided surgery. (1991) (14)
- Receptor-Mediated Radiotherapy With 9~ The Experience of the European Institute of Oncology Group (2002) (14)
- Radionuclide peptide cancer therapy (2006) (14)
- 68Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer (2018) (13)
- Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials (2021) (13)
- Radioimmunoguided surgery and colorectal cancer. (1996) (13)
- 177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study (2020) (13)
- Neoadjuvant therapy in locally advanced breast cancer: 99mTc-MIBI mammoscintigraphy is not a reliable technique to predict therapy response. (2007) (13)
- Fluorodeoxyglucose positron emission tomography in pulmonary carcinoid tumors. (2015) (13)
- Bone scan had no role in the staging of 765 consecutive operable T(1-2)N(0-1) breast cancer patients without skeletal symptoms. (2001) (13)
- Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review. (2020) (13)
- Sentinel node localisation: A new prospective in the treatment of nodal melanoma metastases. (1999) (13)
- Thyroid disease in northern Italian children born around the time of the Chernobyl nuclear accident. (2004) (13)
- Preclinical pharmacology and safety of a novel avidin derivative for tissue-targeted delivery of radiolabelled biotin. (2011) (13)
- Peptide receptor radiotherapy: a new option for the management of aggressive fibromatosis on behalf of the Italian Sarcoma Group (2003) (12)
- Investigation of 18F-FDG PET in the selection of patients with breast cancer as candidates for sentinel node biopsy after neoadjuvant therapy (2010) (12)
- Facts and myths about radiopeptide therapy: Scylla, Charybdis and Sibyl. (2002) (12)
- Preoperative PET/CT in early-stage breast cancer: is the TNM classification enough? (2013) (12)
- Immunoscintigraphy with anti-chromogranin A antibodies inpatients with endocrine/neuroendocrine tumors (1993) (12)
- 68Ga‐ DOTA0‐Tyr3octreotide (DOTATOC) positron emission tomography (PET)/CT in five cases of ectopic adrenocorticotropin‐secreting tumours (2014) (12)
- In vivo imaging of chromogranin A-positive endocrine tumours by three-step monoclonal antibody targeting (1996) (11)
- The humoral immune response to macrocyclic chelating agent DOTA depends on the carrier molecule. (2001) (11)
- 111In-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-lys(8)-vasotocin: a new powerful radioligand for oxytocin receptor-expressing tumors. (2001) (11)
- Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of 225Ac-PSMA (Prostate-Specific Membrane Antigen) (2020) (11)
- [18F]FDG positron emission tomography/computed tomography and multidetector computed tomography roles in thymic lesion treatment planning. (2008) (11)
- Improved immunoscintigraphy by subcutaneous injection of 99mTc or 111In labelled F(ab')2 fragments of an anti-melanoma monoclonal antibody. (1986) (11)
- Sentinel node biopsy in ectopic breast cancer. (2003) (10)
- Investigation of 90Y-avidin for prostate cancer brachytherapy: a dosimetric model for a phase I–II clinical study (2013) (10)
- Membrane IgE binds and activates Fc epsilon RI in an antigen-independent manner. (2005) (10)
- Contralateral or bilateral lymph drainage revealed by breast lymphoscintigraphy (2008) (10)
- Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer (2017) (10)
- Pretargeted radioimmunotherapy. (2020) (10)
- Multidisciplinary approach including receptor radionuclide therapy with 90Y-DOTATOC ([90Y-DOTA0, Tyr3]-octreotide) and 177Lu-DOTATATE ([177Lu-DOTA0, Tyr3]-octreotate) in ectopic cushing syndrome from a metastatic gastrinoma: a promising proposal. (2008) (9)
- Carcinoma, tuberculosis and elastofibroma in one patient: is [18F]FDG-PET/CT helpful? (2009) (9)
- Modification of lymphoscintigraphic sentinel node identification before and after excisional biopsy of primary cutaneous melanoma (2008) (9)
- Immunoscintigraphy of adenocarcinomas by means of 111In-labelled F(ab')2 fragments of anti-CEA monoclonal antibody F023C5. (1988) (9)
- Combination of monoclonal antibodies for radioimmunoguided surgery (1997) (9)
- Yttrium-90 ibritumomab tiuxetan (zevalin) induces high response rates in previously treated patients with diffuse large B cell lymphoma (DLBCL) (2005) (9)
- Antibody-guided scintigraphy: targeting of the “magic bullet” (1993) (8)
- Role of fluorodeoxyglucose positron emission tomography in the staging of patients with breast cancer candidated to surgery. (2006) (8)
- High Dose 90Yttrium Ibritumomab Tiuxetan (Zevalin) with PBSC Support in Refractory-Resistant NHL Patients: A Phase I/II Study. (2006) (8)
- Simple Production of Yttrium-90 in a Chemical form Suitable to Clinical Grade Radioconjugates (1997) (8)
- Clinical utility of 99mTc-Sestamibi scintimammography in the management of equivocal breast lesions. (2004) (8)
- Radiolabeling optimization and reduced staff radiation exposure for high-dose 90Y-ibritumomab tiuxetan (HD-Zevalin). (2010) (8)
- 177Lu-Prostate-Specific Membrane Antigen Ligand After 223Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience (2021) (8)
- Pretargeted antibody‐guided radioimmunotherapy in a child affected by resistant anaplastic large cell lymphoma (2007) (8)
- Yttrium-based therapy for neuroendocrine tumors. (2014) (8)
- Multimodal Approach to Outcome Prediction in Metastatic Castration-Resistant Prostate Cancer by Integrating Functional Imaging and Plasma DNA Analysis. (2019) (8)
- Systemic and locoregional dosimetry in receptor radionuclide therapy with peptides. (2006) (8)
- Changes in alkaline phosphatase (ALP) dynamics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 in an international early access program (EAP). (2016) (8)
- Current status of commercial colloidal preparations for sentinel lymph node detection. (1999) (7)
- Eleven-year experience with the avidin-biotin pretargeting system in glioblastoma: Toxicity, efficacy and survival (2012) (7)
- Pretargeted Radioimmunotherapy of Cancer (2000) (7)
- Clinical value of negative 68Ga-PSMA PET/CT in the management of biochemical recurrent prostate cancer patients (2020) (7)
- 177Lu-PSMA Radioligand Therapy Is Favorable as Third-Line Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials (2021) (7)
- Low dose spiral computed tomography for early diagnosis of lung cancer. Results of baseline screening in 5,000 high-risk volunteers. (2006) (7)
- Biotin derivatives carrying two chelating DOTA units. Synthesis, in vitro evaluation of biotinidases resistance, avidin binding, and radiolabeling tests. (2010) (7)
- Surgery for colorectal cancer guided by radiodetecting probe. Clinical evaluation using monoclonal antibody B72.3. (1991) (7)
- Diagnostic and Prognostic Potential of 18F-FET PET in the Differential Diagnosis of Glioma Recurrence and Treatment-Induced Changes After Chemoradiation Therapy (2021) (7)
- Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging (2021) (7)
- Biodistribution in humans and preliminary clinical evaluation of a new tracer with optimized properties for myocardial perfusion imaging: [99mTc]Q12. (1992) (7)
- Design and solid phase synthesis of new DOTA conjugated (+)-biotin dimers planned to develop molecular weight-tuned avidin oligomers. (2015) (6)
- Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial (2021) (6)
- Radiomics Analysis on [68Ga]Ga-PSMA-11 PET and MRI-ADC for the Prediction of Prostate Cancer ISUP Grades: Preliminary Results of the BIOPSTAGE Trial (2022) (6)
- 68Ga-PSMA-11 PET/CT-Guided Stereotactic Body Radiation Therapy Retreatment in Prostate Cancer Patients with PSA Failure after Salvage Radiotherapy (2020) (6)
- Radioguided Occult Lesion Localization in the Breast (2008) (6)
- Radiology imaging management in an Italian cancer center (IRST IRCCS) during the COVID-19 pandemic (2020) (6)
- A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods. (2020) (6)
- Optimization of antibody labeling with rhenium-188 using a prelabeled MAG3 chelate. (2002) (6)
- Evaluation of four radiopharmaceuticals for imaging inflammation in a rabbit model of arthritis (1996) (5)
- Early use of abiraterone and radium-223 in metastatic prostate cancer. (2019) (5)
- Is CD20 the only target available for radionuclide therapy in lymphoproliferative disorders? (2005) (5)
- Financial aspects of sentinel lymph node biopsy in early breast cancer. (2012) (5)
- Hibernoma Mimicking Metastasis on Positron Emission Tomography–Computed Tomography Imaging: A Misleading Finding in Oncologic Patient Follow‐up (2014) (5)
- Intramedullary spinal cord metastases from breast cancer: detection with 18F-FDG PET/CT (2013) (5)
- Pregnant with metastatic neuroendocrine tumour of the ovary: what now? (2012) (5)
- Exploratory Analysis of 18F-3’-deoxy-3’-fluorothymidine (18F-FLT) PET/CT-Based Radiomics for the Early Evaluation of Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer (2021) (5)
- Localization of biotinylated monoclonal antibodies (B72.3 and F023C5) in patients with colorectal cancer. (1993) (5)
- Testing of microbial contamination during the preparation of the radiocompound [⁹⁰Y]DOTATOC for clinical trials: a process validation study by Media Fill approach. (2010) (5)
- [Radiation protection in the use of tracers in radioguided breast surgery]. (1998) (5)
- Antibody-based cancer therapies: back to “polyclonals”? (2004) (4)
- SUV95th as a Reliable Alternative to SUVmax for Determining Renal Uptake in [68Ga] PSMA PET/CT (2019) (4)
- Pilot therapy trial of CEA positive tumours using a three-step pretargeting approach (1998) (4)
- Therapy Trials in Cancer Patients Using an Improved 3-Step Pretargeting Approach (1997) (4)
- Efficacy of 90Y-Ibritumomab Tiuxetan in Marginal-Zone Lymphoma (MZL). (2007) (4)
- Radionuclide Therapy: Influence of Image Timing, Time-Activity Integration Method, and Risk Factors (2013) (4)
- Something more than estimating renal dosimetry. (2010) (4)
- Production of GMP-compliant lutetium-177: radiochemical precursor for targeted cancer therapy (2010) (4)
- [18F] FDG uptake: pay attention to candies (2007) (4)
- Circulating androgen receptor (AR) gene amplification and resistance to 177Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of a phase II clinical trial. (2019) (4)
- Secondary acute myeloid leukaemia after peptide receptor radionuclide therapy (2012) (4)
- PET/CT and breast cancer subtypes (2013) (4)
- Lymphoscintigraphy and sentinel node biopsy in breast cancer: where are we after 10 years? (2007) (4)
- SSTR5 P335L monoclonal antibody differentiates pancreatic neuroendocrine neuroplasms with different SSTR5 genotypes. (2011) (4)
- High dose 90Yttrium ibritumomab tiuxetan with PBSC support in refractory-resistant NHL patients: Preliminary results of a phase I/II study. (2006) (4)
- SPECT/CT 90Y-Bremsstrahlung images for dosimetry during therapy (2008) (4)
- [177Lu]-PSMA-617 for targeted prostate cancer treatment: a magic bullet? (2018) (4)
- Cerebrospinal fluid diffusion of Zevalin after high-activity treatment and stem cell support in a patient affected by diffuse large B-cell non-Hodgkin's lymphoma with central nervous system involvement. (2005) (3)
- A Blood-Based Multi-Transcript Test - the NETest - Predicts and Defines the Efficacy of Peptide Radio Receptor Therapy in Neuroendocrine Tumors (2016) (3)
- Three‐step tumor targeting via biotin–avidin interaction as a versatile system to elicit T cell‐mediated, non‐MHC‐restricted cytotoxic activity against neoplastic cells (1998) (3)
- Role of sentinel lymph node biopsy in oral cancer Il ruolo del linfonodo sentinella nel carcinoma del cavo orale (2006) (3)
- Targeting of biotinylated anti-tumour monoclonal antibodies by means of radioactive avidin or streptavidin in an animal model (1989) (3)
- Preoperative FDG PET/CT in breast cancer patients: where are we going? (2012) (3)
- Texture analysis in 177Lu SPECT phantom images: Statistical assessment of uniformity requirements using texture features (2019) (3)
- Detection of a cardiac mass by [18F]FDG-PET/CT: a rare case (2009) (3)
- Dosimetric Issues Associated with Percutaneous Ablation of Small Liver Lesions with 90Y (2020) (3)
- Receptor-mediated radiotherapy with 90Y-DOTATOC: Towards the right dose (2000) (3)
- Combined use of111In-labeled pentetreotide and three-step immunoscintigraphy with antichromogranin a monoclonal antibody in the diagnosis of pituitary adenomas (2007) (3)
- Muscle metastases from gallbladder cancer (2011) (3)
- Relation between myocardial 18F‐FDG uptake in the fasting state and coronary angiography in patients with coronary artery disease (1994) (3)
- Spotlight on PSMA as a new theranostic biomarker for bladder cancer (2021) (3)
- Dosimetry Using SPECT-CT (2011) (3)
- Therapy of brain tumors (2007) (3)
- Clinical Study Kidney Dosimetry in 177 Lu and 90 Y Peptide Receptor Radionuclide Therapy : Influence of Image Timing , Time-Activity Integration Method , and Risk Factors (2015) (3)
- Radium-223 with concomitant bone-targeting agents in metastatic castration-resistant prostate cancer (CRPC) patients treated in an international early access program (EAP). (2016) (3)
- Sentinel node detection and radioguided occult lesion localization in breast cancer. (2006) (3)
- Rest distribution of 99mTc-MIBI in patients with coronary artery disease assessed by SPECT: comparison with the distribution of [18F]FDG assessed by PET. (1994) (2)
- A metastatic tumor is no different to a viral pandemic: lessons learnt from COVID-19 may teach us to change the PRRT paradigm (2020) (2)
- [18F]F-PSMA-1007 Radiolabelling without an On-Site Cyclotron: A Quality Issue (2021) (2)
- Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues: ten years experience (2008) (2)
- Combining liquid biopsy and functional imaging analysis in metastatic castration‐resistant prostate cancer helps predict treatment outcome (2021) (2)
- A new microdispersed albumin derivative potentially useful for radio-guided surgery of occult breast cancer lesions (2019) (2)
- [111In]‐DOTA‐Lys8‐Vasotocin: A new promising peptide for oxytocin receptor expressing tumors (2001) (2)
- IART® (Intra-Operative Avidination for Radionuclide Therapy) for accelerated radiotherapy in breast cancer patients. Technical aspects and preliminary results of a phase II study with 90Y-labelled biotin (2010) (2)
- S17 Sentinel Lymphnodes for Localized DCIS (2005) (2)
- Efficacy of 90 Y-Ibritumomab Tiuxetan (Zevalin) in Refractory or Relapsed MALT Gastric Non Hodgkin’s Lymphoma. (2006) (2)
- Usefulness of[111In-DTPA0] octreotide scintigraphy in a family with von Hippel-Lindau disease (2008) (2)
- BIS-1: a novel bispecific monoclonal antibody for CEA-expressing carcinoma radioimmunoscintigraphy and radioimmunotherapy. (1993) (2)
- Use of Tc-99 labelled colloidal albumin for preoperative and intraoperative localization of non-palpable breast lesions (1997) (2)
- Re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020;77: 508-47 https://doi.org/10.1016/j.eururo.2020.01.012. (2020) (2)
- Improper use of “radioguided occult lesion localization” (ROLL) technique leads to misleading conclusions (2013) (2)
- High Dose 90Yttrium Ibritumomab Tiuxetan with PBSC Support in Refractory-Resistant NHL Patients. (2007) (2)
- Overview: Biotinylated Monoclonal Antibodies: Their Potential for Diagnosis and Therapy of Cancer (1993) (2)
- Red Marrow Dosimetry and Stem Cell Reinfusion in High Dose 90 Y - Ibritumomab Tiuxetan. (2008) (2)
- C19Analysis of overall survival by number of radium-223 injections received in an international expanded access program (iEAP) (2016) (2)
- Production and Quality Control of [177Lu]Lu-PSMA-I&T: Development of an Investigational Medicinal Product Dossier for Clinical Trials (2022) (2)
- Benchmark of FLUKA Monte Carlo code for dosimetry in nuclear medicine therapy through electron and isotopes dose point kernel calculation (2011) (2)
- Radiolocalisation of an anti-CEA Monoclonal Antibody (FO23C5) and its Fragments in a Colon Carcinoma Xenograft Model (1988) (2)
- Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumours (2012) (2)
- A new conjugate of human albumin and p-SCN-Bn-DOTA for radioguided occult lesion localization in breast cancer (ROLL) (2014) (2)
- Peptide Receptor Radionuclide Therapy (2010) (2)
- Disease characteristics and outcome of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received a beta emitter (177Lu-PSMA) after an alpha emitter (radium-223). (2020) (2)
- Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration‐resistant cancer patients (2021) (1)
- Acquisition protocol for breast cancer imaging with technetium-99m-labeled synthetic peptide and technetium-99m-MDP. (1997) (1)
- Dosimetric Approaches for Radioimmunotherapy of Non-Hodgkin Lymphoma in Myeloablative Setting. (2022) (1)
- Roles of computed tomography and [18F]fluorodeoxyglucose-positron emission tomography/computed tomography in the characterization of multiple solitary solid lung nodules (2012) (1)
- Development of sentinel node biopsy, ROLL and IART in early breast cancer at the European Institute of Oncology, Milan (IEO) (2017) (1)
- 93 P - Study on sentinel nodes in breast cancer using Lymphoscintigraphy and radio-guided probe (1996) (1)
- The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia and Second Malignancy Following Yttrium-90 Ibritumomab Tiuxetan: 10-Year Single-Institution Experience of 138 Consecutive Patients (2012) (1)
- 0-61. Use of Tc-99 labelled colloidal albumin for preoperative and intraoperative localization of non-palpable breast lesions (1997) (1)
- Early prediction of efficacy of endocrine therapy in breast cancer (BC): Pilot study and validation with 18F fluoroestradiol (18F-FES) PET/CT. (2013) (1)
- Pretargeted Radioimmunotherapy in Cancer: An Overview (2010) (1)
- A surveillance programme for Salmonella infection in poultry: first results. (2000) (1)
- 2577 The correlation between circulating cell-free AR and CYP17A1 copy number variations and tumor burden estimated by 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone (2015) (1)
- Stage migration and micrometastases (2002) (1)
- Are we ready for an early evaluation of the response of axillary lymph node metastases to neoadjuvant therapy? (2011) (1)
- Efficacy of 90Y ibritumomab-tiuxetan treatment in a case of resistant gastric MALT non-Hodgkin’s lymphoma (2008) (1)
- Development of sentinel node localization and ROLL in breast cancer in Europe (2015) (1)
- Peptide Receptor Radionuclide Therapy (PRRT): Clinical Application (2015) (1)
- [The new prospects for radioimmunoguided surgery: the avidin-biotin system]. (1991) (1)
- Diagnostic Applications of Nuclear Medicine: Neuroendocrine Tumors (2016) (1)
- Theragnostic in neuroendocrine tumors. (2021) (1)
- Intraoperative avidination for radionuclide treatment (IART(R)) post quadrantectomy in breast cancer: Predicted dosimetry with 90Y-biotin (2006) (1)
- The failure of clinical factors to predict long-term toxicity after PRRT in >800 patients - Is a genetic screen needed? (2014) (1)
- 08 Sentinel node biopsy: the role of a learning phase (1999) (1)
- Optimised lymphoscintigraphy in pregnant patients with breast cancer is safe (2005) (1)
- A Novel Injectable Hydrogel Matrix Loaded With 90Y Microspheres for the Treatment of Solid Tumors (2022) (1)
- Oral presentations (2011) (1)
- Efficacy of 90 Y - Ibritumomab Tiuxetan in Relapsed or Refractory Primary Gastric Non Hodgkin Lymphoma (2008) (1)
- Neuroendocrine Tumors: Therapy with Radiolabeled Peptides (2016) (1)
- Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumab (2022) (1)
- 09 Sentinel node biopsy: the best method to stage melanoma patients for adjuvant trials (1999) (1)
- Reply to: Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging (2017) (1)
- Peptide receptor radionuclide therapy (PRRT) transcriptomic signature in blood for prediction of 177lu-octreotate efficacy. (2018) (1)
- High dose Y-90-Ibritumomab-Tiuxetan with autologous stem cell transplantation in refractory-resistant NHL patients (2010) (1)
- Personalized 177Lu-dotatate treatment of advanced P-NENs and the value of 18F-FDG PET-CT as a prognostic factor in a long term follow up: our experience. (2016) (1)
- 90Y, 177Lu, and 131I therapy optimisation: Monte Carlo calculation of dose distribution and radiobiological evaluations (2009) (1)
- Is a SUV cut-off necessary in the evaluation of the response of axillary lymph node metastases to neoadjuvant therapy? (2010) (1)
- Perspectives in the development of novel treatment approaches. (2010) (1)
- Clinical Application of the Avidin-Biotin System for Tumor Targeting (2018) (0)
- Sentinel Lymph Node Biopsy in Gynecologic Malignancies (2008) (0)
- Antigen “Suicide”: A Preliminary Study on the Induction of Specific Anti-Immunoglobulin Immunological Suppression in Vivo, Using Radiolabeled Immunoglobulin as “Lethal” Antigen (1994) (0)
- A new microdispersed albumin derivative potentially useful for radio-guided surgery of occult breast cancer lesions (2019) (0)
- The Complex of Monteoliveto (2014) (0)
- Oral Presentations (2006) (0)
- 111In-DOTA-biotin pharmacokinetics after pretargeted intratumoral avidin in a human breast cancer mouse model (2006) (0)
- Randomized, multicentre phase II trial of the sequencing of radium-223 and docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC). (2018) (0)
- Association of plasma tumor DNA (ptDNA) with increased risk of venous thromboembolism (VTE) in metastatic castration resistant prostate cancer patients (mCRPC). (2021) (0)
- Oral Presentations (2019) (0)
- Increased choline uptake in androgen receptor (AR) copy number gain castration-resistant prostate cancers (CRPC) (2016) (0)
- Comparing quantitative parameters for diagnostic evaluation of [18F]fluorodeoxyglucose uptake in early breast cancer (2011) (0)
- Retreatment with low dose 177Lu-dotatate (Lu-PRRT), in patients with GEP NENs: A prospective feasibility and activity evaluation (2014) (0)
- Efficacy of 90yttrium-Ibritumomab Tiuxetan in Extranodal Marginal-Zone Lymphoma, (2011) (0)
- Oxadivin reacts with tissues and efficiently uptakes biotinylated therapeutics (2009) (0)
- Avidin-biotin approach for cancer therapy and new biotin derivatives (2021) (0)
- Radioligand therapies in cancer: mapping the educational landscape in Europe. (2023) (0)
- 177Lu-DOTATATE receptor radionuclide therapy: Internal dosimetry estimates and considerations for practical protocols (2011) (0)
- Local accelerated radionuclide breast irradiation: Avidin-biotin targeting system (2013) (0)
- Front & Back Matter (2012) (0)
- A drug for perioperative therapy in two steps of solid tumors (2004) (0)
- [Tenascin in breast carcinoma: distribution and significance]. (1992) (0)
- Association of changing bone metastatic (mets) patterns with dynamics of circulating tumor DNA (ctDNA) in metastatic castration-resistant prostate cancer (mCRPC). (2022) (0)
- SNOLL technique in 959 patients with non-palpable breast cancer (2006) (0)
- IntegoTM Infusion System: cost effectiveness analysis focusing on dosimetry, sterility and management. (2019) (0)
- Combining molecular and functional imaging in metastatic castration-resistant prostate cancer (mCRPC). (2021) (0)
- Hematologic toxicity and double autografting of stem cells after myeloablative activities of yttrium-90-ibritumomab tiuxetan. (2009) (0)
- PCN224 An Italian Experience: How the COVID-19 Era HAS Modified the Radiological Activity in a Cancer Hospital (2020) (0)
- ADVANTAGE OF DOSIMETRY IN RADIONUCLIDE THERAPY (2009) (0)
- Bilateral lymphoscintigraphy with an anti-melanoma peptide and sentinel node biopsy: 309 (1997) (0)
- Safety And Clinical Outcomes Of Radium-223 With Concomitant Radiotherapy Or Subsequent Treatment With The Investigational Agent 177Lu-PSMA In Patients With Metastatic Castration-Resistant Prostate Cancer: An Interim Analysis Of The REASSURE Study (2020) (0)
- 0091 Sentinel node biopsy after previous breast surgery: Increasing evidence (2009) (0)
- Prostate-specific membrane antigen and renal cell carcinoma: a new diagnostic and therapeutic target? (2018) (0)
- An insoluble conjugate of human albumin and 2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (p-SCN-Bn-DOTA) for Radioguided Occult Lesion Localization in Brest Cancer (2014) (0)
- Container for glass vials for radio-pharmaceuticals and set for its infusion in a patient or for its transfer to another place (2003) (0)
- 66 Radioantibodies: Monoclonals or “poly-clonals”? (2006) (0)
- LONGROLL: a new human albumin conjugate for radioguided localization of non-palpable breast cancer lesion (2014) (0)
- The Role of Nuclear Medicine in the Treatment of Liver Metastases (1998) (0)
- Circulating neuroendocrine tumor gene expression is effective in monitoring peptide receptor radionuclide (PRRT) efficacy (2018) (0)
- Biotin-diamino derivatives and their conjugated with the macrocyclic chelating agents (2006) (0)
- Peptide receptor radionuclide therapy can be effective in advanced thymus tumors (2012) (0)
- 177Lu-DOTATATE Efficacy and Safety in Functioning Neuroendocrine Tumors: A Joint Analysis of Phase II Prospective Clinical Trials (2022) (0)
- Lymphoscintigraphy of the breast for sentinel node detection (2002) (0)
- Container for radiopharmaceutical vial and insert the infusion resulting in a patient or for the transfer thereof elsewhere (2003) (0)
- Annals of Oncology Institution: GOT (Consortium) Sign In as Personal Subscriber (2009) (0)
- 974 New developments of nuclear medicine in diagnosis and treatment: The pretargeting approach (1995) (0)
- 820PCombining functional imaging with circulating biomarker analysis to improve prognostication of metastatic castration-resistant prostate cancer (mCRPC) (2017) (0)
- Role of sentinel lymph node biopsy in oral cancer-0392-100X.26.345 (2016) (0)
- [Papillary carcinoma of the thyroid. Analysis of survival in 186 cases]. (1985) (0)
- Conjugates of antibodies and metal chelates in cancer therapy (1995) (0)
- Efficacy and toxicity of 90Y-DOTA-biotin after pretargeted intratumoral avidin in mice implanted with human breast cancer (HBT 3477) (2006) (0)
- Pet in intracranial tumors (1993) (0)
- Consensus assessment : Imaging and Biomarkers in Gastroenteropancreatic 1 Neuroendocrine Tumour Disease Management (2016) (0)
- Tumor Cell Targetingwith Antibody-AvidinComplexesand BiotinylatedTumor (1997) (0)
- Intracavitary Use of Radionuclides and Treatment of Meningiomas (2012) (0)
- Sentinel Node Biopsy and Occult Lesion Localization in Early Breast Cancer (2007) (0)
- 3D-dosimetry and radiobiological evaluations in early breast cancer patients undergoing intraoperative avidination for radionuclide therapy (IART) (2011) (0)
- On the Way for Patients with Prostate Cancer to the Best Use of PSMA (2022) (0)
- Erratum to: Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE (2016) (0)
- 177Lu specific activity influence over DOTATATE radiolabeling: experimental data (2008) (0)
- Receptor Radionuclide Therapy with 90Y-[DOTA0]-Tyr3-Octreotide (90Y-DOTATOC): The IEO Experience (2016) (0)
- SUV 95th as a reliable alternative to SUV max for determining renal uptake in 68Ga-PSMA PET/CT (2022) (0)
- Radioimmunoscintigraphy with melanoma-associated monoclonal antibodies in uveal melanoma: Clinical study of 22 patients (1993) (0)
- Biotinylated monoclonal antibodies and in vivo diagnosis of neoplastic recurrences (1995) (0)
- 10. Perspectives in the Development of Novel Treatment Approaches (2010) (0)
- Sentinel nodes scintigraphy of the internal mammary chain in breast cancer (2003) (0)
- 100. 177Lu-PSMA molecular radiotherapy: Strategy to reduce organ at risks uptake (2018) (0)
- Radiation protection in receptor mediated radiotherapy with 90Y (2000) (0)
- REPORTE CORTO/SHORT REPORT - THREE-STEP IMMUNOSCINTIGRAPHY WITH THE AVIDIN-BIOTIN SYSTEM: STATE OF THE ART AND FUTURE PROSPECTIVES (1995) (0)
- Modelling a new approach for radio-ablation after resection of breast ductal carcinoma in-situ based on the BAT-90 medical device (2022) (0)
- Radiolocalization of 99mTc-labeled fragments in a melanoma xenografted model. (1991) (0)
- Lymphoscintigraphy: a method to detect unexpected sites of drainage of breast cancer. (2004) (0)
- New circulating biomarkers in gastro-entero-pancreatic-neuroendocrine-tumours (2019) (0)
- PET imaging of HER-2-positive tumours (2011) (0)
- Results of annual screening of lung cancer with low dose computed tomography in 5,000 high-risk individuals (2007) (0)
- Yttrium-90 Labelled Anti-CD20 Radioimmunotherapy with Stem Cells Support (2012) (0)
- PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis (2018) (0)
- 3-Step Radioimmunotherapy in Advanced Ovarian Cancer (2002) (0)
- IntraoperativeAvidination for RadionuclideTherapy : AProspective New Development toAccelerate Radiotherapy in Breast Cancer (2007) (0)
- Contents Vol. 97 (2013) (0)
- Importance of PET with 68Ga-Labeled Somatostatin Analogs. (2020) (0)
- Radioimmimotherapy in high grade gliomas (2007) (0)
- Detection and biopsy of sentinel nodes of the internal mammary chain in breast cancer (2002) (0)
- Abstract Joint Meeting on Senology Florence, Italy, 18–22 March 1997 European Society of Mastology: Abstract and PorterUse OT Tc-99 labelled colloidal albumin for preoperative and intraoperative localization of non-palpable breast lesions (1997) (0)
- Right pelvic mass in a patient with a radically resected carcinoid of the appendix (2009) (0)
- Integrating targeted treatments with tumor biology and molecular imaging in the current and future management of neuroendocrine gastrointestinal tumors (2012) (0)
- Institutional guidelines and ongoing studies in management of liver tumours: the experience of the European Institute of Oncology (2008) (0)
- SYMPOSIUM OF BREAST IMAGING Innovation in early breast cancer surgery: radio-guided occult lesion localization and sentinel node biopsy (2002) (0)
- Neuroendocrine tumour management (2013) (0)
- Investigation of 18F-FDG PET in the selection of patients with breast cancer candidate to sentinel node biopsy after neoadjuvant therapy - Update of an ongoing study (2011) (0)
- miR-196a Is Specifically Regulated in FDG-PET Positive and Negative Small Intestinal Neuroendocrine Tumor Patients at Late Stage of Disease (2016) (0)
- Targeted radioactive therapy for prostate cancer (2021) (0)
- Author Correction: A new microdispersed albumin derivative potentially useful for radio-guided surgery of occult breast cancer lesions (2020) (0)
- Dosimetric Model for Locoregional Treatments (2005) (0)
- In Vivo Models for the Performance and Safety of BAT-90, a Novel 90-Yttrium-based Internal Radiotherapy Platform (2022) (0)
- PRRT neuroendocrine tumor response assessment using blood transcript analysis: The NETest. (2020) (0)
- Container for radiopharmaceutical vial, and equipment for its infusion in a patient or for its transfer elsewhere. (2002) (0)
- Abstract 3106: A blood-based neuroendocrine tumor multi-transcript test predicts and defines PRRT efficacy in neuroendocrine tumors (2016) (0)
- Poster walks (2010) (0)
- 18F-fluorocholine positron emission tomography/computed tomography for early outcome prediction in metastatic castration-resistant prostate cancer patients treated with enzalutamide: A proof-of-principle study. (2014) (0)
- A predictive quotient index, comprising neuroendocrine gene cluster analysis in blood and tissue grading is specifically predicts PRRT efficacy (2017) (0)
- Comparing outcomes from CT and PET imaging after tumor liver radioembolization with 90Y-microspheres might suggest more appropriate choice of response evaluation (2011) (0)
- Author Correction: A new microdispersed albumin derivative potentially useful for radio-guided surgery of occult breast cancer lesions (2020) (0)
- High dose radioimmunotherapy with Zevalin(R) in refractory-resistant non Hodgkin's lymphoma: Preliminary results (2006) (0)
- A novel three-step immunoscintigraphy employing an anti-ferritin antibody to detect hepatocellular carcinoma (1995) (0)
- 31st Symposium Radioactive Isotopes in Molecular Imaging (former Gastein Meeting) (2013) (0)
- 31 P - Immunolymphoscintigraphy and sentinel node biopsy in melanoma (1996) (0)
- P76 Clinical experiences with therapeutic derivatives of the anti-ED-B fibronectin immunoprotein L19 (2007) (0)
- INTRAOPERATIVE β- DETECTING PROBE FOR RADIO-GUIDED SURGERY OF BRAIN TUMORS (2014) (0)
- Nodules Detected at Baseline Computed Tomography Screening Role of Positron Emission Tomography Scanning in the Management of Lung (2013) (0)
- 9207 Efficacy of 90Yttrium-ibritumomab tiuxetan in extranodal marginal-zone lymphoma (2009) (0)
- Abstract 1789: A gene expression-based nomogram predicts overall and progression free survival in PRRT-treated gastroenteropancreatic neuroendocrine tumors (2017) (0)
- Intraoperative beta- detecting probe for radio-guided surgery of brain tumors (2014) (0)
- Low dosage 177LuDOTATATE (177LuPRRT) re-treatment in GEP-NEN patients who relapse after 177LuPRRT (2016) (0)
- novel biotin derivative carrying two DOTA groups of potential interest to increase the tumor dose (2006) (0)
- 3-step Locoregional Radioimmunotherapy with 90Y-biotin a Phase I-II Study (2002) (0)
- Reply to the Letter to the Editor on Safety of sentinel node biopsy in pregnant patients, by G. Dubernard et al. (Ann Oncol 2005; 16: 987) (2005) (0)
- Radioimmunotherapy in Brain Tumors (2013) (0)
- 606P Novel miRNA-based assay for GEP-NENs management (2020) (0)
- A parathyroid carcinoma within a cold thyroid nodule (2009) (0)
- 3-Step radioimmunotherapy (RIT) in high-grade glioma: 11 Years experience with the avidin-biotin system (2010) (0)
- Voxel-dosimetry as useful tool for optimized administered activity in radioembolization of liver tumors with 90Y-microspheres (2011) (0)
- Nuclear Medicine in the Clinical Management (ROLL, SNB, and PET) (2017) (0)
- Modelling a new approach for radio-ablation after resection of breast ductal carcinoma in-situ based on the BAT-90 medical device (2022) (0)
- 18F-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY WITH COMPUTED TOMOGRAPHY IMAGES FUSION FOR THE DETECTION OF COLORECTAL ADENOMAS (2009) (0)
- Circulating neuroendocrine transcripts and gene cluster analysis to predict the efficacy of peptide radioreceptor therapy. (2016) (0)
- Role of Functional Imaging in the Diagnosis of Neuroendocrine Tumors (2018) (0)
- PSMA PET/CT and radiotherapy in prostate cancer: a winning team (2022) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Giovanni Paganelli?
Giovanni Paganelli is affiliated with the following schools:
